INTRODUCTION
Multiple sclerosis (MS) is an inflammatory, demyelinating disease involving the white matter of the central nervous system. Worldwide, approximately 1 million individuals are afflicted, with approximately 300,000 people suffering from MS in the United States. Women with the disease outnumber men 2:1. Manifestations of clinical disease usually commence in early adulthood. Paralysis, sensory disturbances, incoordination, and visual impairment are common features. The disease often starts with periods of exacerbation, followed by remission, and then enters after some years into a chronic progressive state. The exact cause of the disease is unknown. However, MS has conspicuous features of an autoimmune disease (Steinman, 1996a) . Recent studies have elucidated some intriguing clues about the genes and the environmental factors that contribute to its pathogenesis (Karpuj et al., 1997) . Increased understanding of the pathobiology of MS is leading to new therapeutic approaches, now being tested in clinical trials. In addition, understanding the mechanisms of action of some recently approved drugs is actually broadening our knowledge of the pathophysiology of this disease. This should lead to further insights, culminating in ever-improved treatments.
The classical pathology of MS is recorded entirely in the central nervous system (CNS) and is characterized by inflammation surrounding venules and extending into the myelin sheath. MS resembles acute disseminated encephalomyelitis (ADE) and its animal model experimental autoimmune encephalomyelitis (EAE). ADE, acute transverse myelopathy (ATM), and acute optic neuritis (AON) may represent monophasic acute versions of MS. The factors leading to the development of chronic autoimmune disease like MS, rather than the self-contained diseases like ADE, ATM, or AON, are unknown, but are likely to be extremely important. In MS, ADE, ATM, and AON and EAE, the immune system may actually become activated outside the nervous system, by microbes or environmental factors with no direct relationship to the central nervous system. In this review we shall describe current understanding of MS including the pathobiology of the autoimmune attack, the genetic factors underlying susceptibility, and the environmental factors which influence the course of the disease. Understanding the pathogenesis of MS allows for the rational design of new therapeutic strategies, some of which have been approved by the U.S. Food and Drug Administration and others which are now in clinical trials. These new approaches to treatment will be discussed. 149-166 (1999) Article ID nbdi.1999.0239 , available online at http://www.idealibrary.com on
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